Latest Pharma Insights
Mahl Takes Charge At Fresenius Kabi As Antonelli Departs
Fresenius Kabi has announced a leadership change that will see Marc-Alexander Mahl take over responsibility of the business from current CEO Pierluigi Antonelli at the start of November. Meanwhile, Fresenius chief financial officer Sara Hennicken has seen her contract extended by another five years.
Generics Bulletin - October 16, 2026
Fresenius Kabi has announced a leadership change that will see Marc-Alexander Mahl take over responsibility of the business from current CEO Pierluigi Antonelli at the start of November. Meanwhile, Fresenius chief financial officer Sara Hennicken has seen her contract extended by another five years.
Generics Bulletin - October 16, 2026
Callio Needs ‘Next Bolus Of Capital’ Soon As Dual-Payload ADCs Heat Up
The new CEO of Callio Therapeutics, which has been on the vanguard of companies focused on dual-payload ADCs, talks to Scrip in an exclusive interview about his priorities, including plans to raise funds next year.
Scrip - October 16, 2026
The new CEO of Callio Therapeutics, which has been on the vanguard of companies focused on dual-payload ADCs, talks to Scrip in an exclusive interview about his priorities, including plans to raise funds next year.
Scrip - October 16, 2026
EMA Gives Green Light To EU-Wide Switch Of Opioid Overdose Spray Nyxoid
The European Medicines Agency’s human medicines committee has backed making naloxone nasal spray Nyxoid available without prescription across all EU member states. Applicant Mundipharma says approval would meet a "significant need" to widen access to an emergency treatment for opioid overdose.
HBW Insight - October 16, 2026
The European Medicines Agency’s human medicines committee has backed making naloxone nasal spray Nyxoid available without prescription across all EU member states. Applicant Mundipharma says approval would meet a "significant need" to widen access to an emergency treatment for opioid overdose.
HBW Insight - October 16, 2026
Faster Decisions And Earlier Access: UK Generics Industry Welcomes MHRA’s 2030 Targets
Medicines UK has welcomed targets set as part of the newly-unveiled MHRA Strategy 2030, including making faster decisions on generics and biosimilars and also deepening engagement with international markets such as India.
Generics Bulletin - October 16, 2026
Medicines UK has welcomed targets set as part of the newly-unveiled MHRA Strategy 2030, including making faster decisions on generics and biosimilars and also deepening engagement with international markets such as India.
Generics Bulletin - October 16, 2026
Beyond AlphaFold: Immuto Bets Protein Conformations Hold The Next Cancer Targets
Immuto Scientific bets reading protein shapes on living tumor cells can steer antibodies to targets that genomics and expression profiling miss and the company has partnered Daiichi Sankyo and UW-Madison on this basis, Immuto co-founder Daniel says.
In Vivo - October 16, 2026
Immuto Scientific bets reading protein shapes on living tumor cells can steer antibodies to targets that genomics and expression profiling miss and the company has partnered Daiichi Sankyo and UW-Madison on this basis, Immuto co-founder Daniel says.
In Vivo - October 16, 2026
ProKidney Is Betting A Cell Therapy Phase III Readout Can Fund Its Way To Market
Pivotal data are due in the second quarter of 2027, around when the company’s money is guided to run out. CEO Bruce Culleton spoke to In Vivo on the science, the procedure and the balance sheet.
In Vivo - October 16, 2026
Pivotal data are due in the second quarter of 2027, around when the company’s money is guided to run out. CEO Bruce Culleton spoke to In Vivo on the science, the procedure and the balance sheet.
In Vivo - October 16, 2026
US FDA Wants Advisory Committee Members, But Not Voting Consumer Reps
A nationwide nomination push is a sharp break from former Commissioner Martin Makary’s aversion to advisory committees, even as charter renewals have quietly moved most drug and biologic consumer representative seats to nonvoting status.
HBW Insight - October 16, 2026
A nationwide nomination push is a sharp break from former Commissioner Martin Makary’s aversion to advisory committees, even as charter renewals have quietly moved most drug and biologic consumer representative seats to nonvoting status.
HBW Insight - October 16, 2026
Callio Needs ‘Next Bolus Of Capital’ Soon As Dual-Payload ADCs Heat Up
The new CEO of Callio Therapeutics, which has been on the vanguard of companies focused on dual-payload ADCs, talks to Scrip in an exclusive interview about his priorities, including plans to raise funds next year.
Scrip - October 16, 2026
The new CEO of Callio Therapeutics, which has been on the vanguard of companies focused on dual-payload ADCs, talks to Scrip in an exclusive interview about his priorities, including plans to raise funds next year.
Scrip - October 16, 2026
Stryker’s $400M Funding In CMR Surgical ‘Gives It Another Potential Growth Vertical,’ Analysts Say
Stryker’s $400m CMR Surgical stake, with exclusive US sales rights and a buyout option, opens a soft-tissue robotics vertical aimed at outpatient centers.
Medtech Insight - October 15, 2026
Stryker’s $400m CMR Surgical stake, with exclusive US sales rights and a buyout option, opens a soft-tissue robotics vertical aimed at outpatient centers.
Medtech Insight - October 15, 2026
Labcorp To Pay Up To $872M For BioReference Health Assets, Including 4Kscore Prostate Test
Labcorp will pay $722m in cash at closing, plus up to $150m tied to revenue, for BioReference Health’s labs, more than 80 patient service centers and the FDA-approved prostate cancer test. Parent company OPKO says the sale lets it focus on its biopharmaceutical business.
Medtech Insight - October 15, 2026
Labcorp will pay $722m in cash at closing, plus up to $150m tied to revenue, for BioReference Health’s labs, more than 80 patient service centers and the FDA-approved prostate cancer test. Parent company OPKO says the sale lets it focus on its biopharmaceutical business.
Medtech Insight - October 15, 2026
Execs On The Move: October 5–9, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - October 15, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - October 15, 2026
EMA Gives Green Light To EU-Wide Switch Of Opioid Overdose Spray Nyxoid
The European Medicines Agency’s human medicines committee has backed making naloxone nasal spray Nyxoid available without prescription across all EU member states. Applicant Mundipharma says approval would meet a "significant need" to widen access to an emergency treatment for opioid overdose.
HBW Insight - October 16, 2026
The European Medicines Agency’s human medicines committee has backed making naloxone nasal spray Nyxoid available without prescription across all EU member states. Applicant Mundipharma says approval would meet a "significant need" to widen access to an emergency treatment for opioid overdose.
HBW Insight - October 16, 2026
US FDA Wants Advisory Committee Members, But Not Voting Consumer Reps
A nationwide nomination push is a sharp break from former Commissioner Martin Makary’s aversion to advisory committees, even as charter renewals have quietly moved most drug and biologic consumer representative seats to nonvoting status.
HBW Insight - October 16, 2026
A nationwide nomination push is a sharp break from former Commissioner Martin Makary’s aversion to advisory committees, even as charter renewals have quietly moved most drug and biologic consumer representative seats to nonvoting status.
HBW Insight - October 16, 2026
Mahl Takes Charge At Fresenius Kabi As Antonelli Departs
Fresenius Kabi has announced a leadership change that will see Marc-Alexander Mahl take over responsibility of the business from current CEO Pierluigi Antonelli at the start of November. Meanwhile, Fresenius chief financial officer Sara Hennicken has seen her contract extended by another five years.
Generics Bulletin - October 16, 2026
Fresenius Kabi has announced a leadership change that will see Marc-Alexander Mahl take over responsibility of the business from current CEO Pierluigi Antonelli at the start of November. Meanwhile, Fresenius chief financial officer Sara Hennicken has seen her contract extended by another five years.
Generics Bulletin - October 16, 2026
Faster Decisions And Earlier Access: UK Generics Industry Welcomes MHRA’s 2030 Targets
Medicines UK has welcomed targets set as part of the newly-unveiled MHRA Strategy 2030, including making faster decisions on generics and biosimilars and also deepening engagement with international markets such as India.
Generics Bulletin - October 16, 2026
Medicines UK has welcomed targets set as part of the newly-unveiled MHRA Strategy 2030, including making faster decisions on generics and biosimilars and also deepening engagement with international markets such as India.
Generics Bulletin - October 16, 2026
Beyond AlphaFold: Immuto Bets Protein Conformations Hold The Next Cancer Targets
Immuto Scientific bets reading protein shapes on living tumor cells can steer antibodies to targets that genomics and expression profiling miss and the company has partnered Daiichi Sankyo and UW-Madison on this basis, Immuto co-founder Daniel says.
In Vivo - October 16, 2026
Immuto Scientific bets reading protein shapes on living tumor cells can steer antibodies to targets that genomics and expression profiling miss and the company has partnered Daiichi Sankyo and UW-Madison on this basis, Immuto co-founder Daniel says.
In Vivo - October 16, 2026
ProKidney Is Betting A Cell Therapy Phase III Readout Can Fund Its Way To Market
Pivotal data are due in the second quarter of 2027, around when the company’s money is guided to run out. CEO Bruce Culleton spoke to In Vivo on the science, the procedure and the balance sheet.
In Vivo - October 16, 2026
Pivotal data are due in the second quarter of 2027, around when the company’s money is guided to run out. CEO Bruce Culleton spoke to In Vivo on the science, the procedure and the balance sheet.
In Vivo - October 16, 2026